Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 4/20 | 0.39 |
| ▸ | CLPP | Q16740 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20593214 | 0.86 | CCNT1 (0.38) | KMT2AMEN1ALDH1A1TP53CFTR | |
| SCHEMBL21385394 | 0.84 | GRM5 (0.47) | KMT2AALDH1A1NAMPTMAPK1KDM4E | |
| Trifluoroacetic Acid SCHEMBL20593231 | 0.84 | CLPP (0.40) | KMT2AMEN1ALDH1A1TP53CFTR | |
| SCHEMBL21385436 | 0.77 | C5AR1 (0.42) | KMT2AMEN1CFTRCLPPSMN1; SMN2 | |
| SCHEMBL21385389 | 0.74 | MEN1 (0.46) | KMT2AMEN1CLPPRAB9ANPC1 | |
| SCHEMBL11947240 | 0.73 | KMT2A (0.49) | KMT2AMEN1ALDH1A1TP53CFTR | |
| Trifluoroacetic Acid SCHEMBL20593376 | 0.72 | PDK1 (0.34) | P2RX7 | |
| SCHEMBL1911808 | 0.70 | KMT2A (0.52) | KMT2AMEN1ALDH1A1TP53CLPP | |
| SCHEMBL30767848 | 0.68 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CLPPKDM4E | |
| SCHEMBL322777 | 0.68 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CLPPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180370990-A1 | TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370990-A1 | TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE | ATR, DTYMK, CHEK1 | KMT2A 1160/4885MEN1 3160/4885ALDH1A1 3090/4885 |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KMT2A 1160/4885MEN1 3160/4885ALDH1A1 3090/4885 |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KMT2A 1160/4885MEN1 3160/4885ALDH1A1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.